Schizophrenia  >>  Vabicaserin (PF-05208769)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vabicaserin (PF-05208769) / Pfizer
NCT00447941: Safety, PK and PD Study in Healthy Male Japanese Subjects

Completed
1
24
Japan
SCA-136
Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
08/06
08/06
NCT00458107: Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects

Completed
1
64
US
SCA-136
Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
 
09/07
NCT00505973: Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

Completed
1
24
Japan
SCA-136
Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
 
10/07
NCT00541996: Study Comparing Bioavailability of Oral Formulations of Vabicaserin

Completed
1
US
vabicaserin
Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
 
10/07

Download Options